Introduction
Human Monkeypox, now referred to by the WHO as Mpox, is caused by the Monkeypox Virus (MPV) [1]. The MPV was first isolated in 1958 in a laboratory facility in Denmark, which later became endemic in Central and West Africa [2]. Interestingly, amidst the COVID-19 pandemic, Mpox reemerged as a global concern starting in May 2022, as an increasing number of active cases and mortalities in non-endemic countries were reported in different parts of the world. Mpox produced similar presentations, although considered much milder, to the lethal smallpox virus, predominantly presenting as skin rash and with a mortality rate ranging from 1-10%. Notable complications of Mpox included secondary bacterial infections, respiratory distress, bronchopneumonia, encephalitis, corneal infection with ensuing loss of vision, as well as gastrointestinal involvement, such as vomiting and diarrhea with dehydration [3]. To date, gastrointestinal manifestation in Mpox patients remains poorly understood and characterized, as there is an evident lack of literature. This systematic review aims to summarize available evidence regarding the prevalence of gastrointestinal manifestations in Mpox patients from available reports and studies.